The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | A key take-home message from the EBMT-EHA CAR T-Cell Meeting
Here, Graham Collins, MBBS, MRCP, FRCPath, DPhil, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, describes the most exciting aspect of CAR T-cell therapy currently. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Dr Collins explains the key issues with CAR T-cell therapy and the interesting presentations from the meeting that aim to address these issues. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA).
